Researchers develop Alzheimer's drug RI-AG03 targeting Tau protein, showing promising results in lab studies.

Researchers from Lancaster University and other institutions have developed a promising Alzheimer's drug, RI-AG03, which targets two key areas of the Tau protein associated with the disease. In laboratory and fruit fly studies, the drug effectively prevented Tau protein build-up, potentially leading to improved treatments for neurodegenerative diseases. Future testing will involve rodents before advancing to clinical trials.

October 03, 2024
27 Articles